The following protocol covers empiric antibiotic management for adults admitted to hospital with nonsevere community-acquired pneumonia (CAP) caused by Moraxella catarrhalis, in whom there are no identified risk factors for MRSA or Pseudomonas aeruginosa.
Adult inpatient with nonsevere community-acquired pneumonia, without risk factors for MRSA or Pseudomonas aeruginosa. This risk-stratified profile determines which empiric regimens are appropriate — the full selection and sequencing are covered in the complete protocol.
Guideline-recommended empiric therapy includes both combination antibiotic regimens and a monotherapy option, with an alternative approach available when specific drug classes are contraindicated. The complete regimen — including agents, sequencing, and the criteria for switching to oral therapy — is set out in the full protocol.
Clinical stability: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation. Most patients achieve clinical stability within the first 48 to 72 hours.
DOI: 10.1164/rccm.201908-1581ST
In inpatient adults with nonsevere CAP without risk factors for MRSA or P. aeruginosa (see Recommendation 11), we recommend the following empiric treatment regimens (in no order of preference) (Table 4).
A variety of criteria for determining clinical improvement have been developed for patients with CAP and validated in clinical trials, including resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation.
View source ↗